Sensitivity (+) |
AKT1 somatic variants,
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
AKT1 somatic variants,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
AKT1 somatic variants,
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
AKT1 amplification,
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
AKT1 amplification,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
AKT1 amplification,
ER positive,
HER2-negative,
PR positive
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
AKT1 amplification,
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
AKT1 somatic variants,
ER positive,
HER2-negative
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|